Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
The treatment of fibrocavitatory pulmonary infection due to Mycobacterium avium complex and Mycobacterium malmoense poses a challenge. This study assessed microbial, inflammatory, radiographic, and clinical outcomes for a standardized 24-month triple-drug regime. Following treatment completion, all patients had fewer symptoms, experienced a reduction in systemic inflammation, and had negative sputum mycobacterial culture results.
Murray
Maeve P
MP
Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. maevemurray@hotmail.com
Laurenson
Ian F
IF
Hill
Adam T
AT
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001799:Blood Sedimentation; D002939:Ciprofloxacin / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D009162:Mycobacterium avium / Q000187:drug effects / Q000302:isolation & purification; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis / Q000188:drug therapy*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects / Q000302:isolation & purification; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage*; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D004977:Ethambutol; D017291:Clarithromycin; D012293:Rifampin